Melinda L Telli

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 8

Top Venues

Breast cancer (Tokyo, Japan)

Nature cancer

JNCI cancer spectrum

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Melinda L Telli, Jennifer K Litton, J Thaddeus Beck, Jason M Jones, Jay Andersen, Lida A Mina, Raymond Brig, Michael Danso, Yuan Yuan, William F Symmans, Julia F Hopkins, Lee A Albacker, Antonello Abbattista, Kay Noonan, Marielena Mata, A Douglas Laird, Joanne L Blum
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status. Breast cancer (Tokyo, Japan) 31 (5) (2024)
Melinda L Telli, Jennifer K Litton, J Thaddeus Beck, Jason M Jones, Jay Andersen, Lida A Mina, Raymond Brig, Michael Danso, Yuan Yuan, William F Symmans, Julia F Hopkins, Lee A Albacker, Antonello Abbattista, Kay Noonan, Marielena Mata, A Douglas Laird, Joanne L Blum
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status. Breast cancer (Tokyo, Japan) (2024)
Julia D Ransohoff, Iain Miller, Jocelyn Koo, Vishal Joshi, Allison W Kurian, Kimberly H Allison, Isabelle Durot, Melinda L Telli
Tumor-infiltrating lymphocytes and breast cancer mortality in racially and ethnically diverse participants of the Northern California Breast Cancer Family Registry. JNCI cancer spectrum 8 (2) (2024)
Melinda L Telli, Jennifer K Litton, J Thaddeus Beck, Jason M Jones, Jay Andersen, Lida A Mina, Raymond Brig, Michael Danso, Yuan Yuan, William F Symmans, Julia F Hopkins, Lee A Albacker, Antonello Abbattista, Kay Noonan, Marielena Mata, A Douglas Laird, Joanne L Blum
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status. Breast cancer (Tokyo, Japan) 31 (5) (2024)
Melinda L Telli, Jennifer K Litton, J Thaddeus Beck, Jason M Jones, Jay Andersen, Lida A Mina, Raymond Brig, Michael Danso, Yuan Yuan, William F Symmans, Julia F Hopkins, Lee A Albacker, Antonello Abbattista, Kay Noonan, Marielena Mata, A Douglas Laird, Joanne L Blum
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status. Breast cancer (Tokyo, Japan) 31 (5) (2024)
Julia D Ransohoff, Victor Ritter, Natasha Purington, Karen Andrade, Summer Han, Mina Liu, Su-Ying Liang, Esther M John, Scarlett L Gomez, Melinda L Telli, Lidia Schapira, Haruka Itakura, George W Sledge, Ami Siddharth Bhatt, Allison W Kurian
Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer. Nature communications 14 (1) (2023)
Joshua J Gruber, Anosheh Afghahi, Kirsten Timms, Alyssa DeWees, Wyatt Gross, Vasily N Aushev, Hsin-Ta Wu, Mustafa Balcioglu, Himanshu Sethi, Danika Scott, Jessica Foran, Alex McMillan, James M Ford, Melinda L Telli
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. Nature cancer 3 (10) (2022)
Melinda L Telli, Jessica Hellyer, William Audeh, Kristin C Jensen, Shikha Bose, Kirsten M Timms, Alexander Gutin, Victor Abkevich, Rebecca N Peterson, Chris Neff, Elisha Hughes, Zaina Sangale, Joshua Jones, Anne-Renee Hartman, Pei-Jen Chang, Shaveta Vinayak, Richard Wenstrup, James M Ford
Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer. Breast cancer research and treatment 168 (3) (2017)

Melinda L Telli.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Melinda L Telli